You are here
Anne Tsao, MD
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Anne Tsao is Professor of Medical Oncology at the University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA. She specializes in thoracic medical oncology and is a leader in her field for the study of malignant mesothelioma and thoracic oncology. Dr Tsao earned her medical degree from the University of Chicago Pritzker School of Medicine, Chicago, IL, USA, and completed an internship and a residency at Indiana University in Indianapolis, IN, USA, and a medical oncology fellowship at the MDACC. After completing her training, she joined the faculty at MDACC; being board certified in both internal medicine and medical oncology, Dr Tsao specializes in thoracic medical oncology, and currently serves as both the director of the mesothelioma program and the director of the thoracic chemo-radiation program.
Dr Tsao’s research focuses on individualizing cancer therapy through understanding the molecular mechanisms of disease; she is the principle investigator of several active clinical trials at MDACC and also serves as Co-Chair of the MDACC Clinical Research Committee.
Dr Tsao has received many awards, including an American Society of Clinical Oncology (ASCO) Merit Award, the MD Anderson Achievement in Research Award, and the ASCO Young Investigator Award. She has authored or co-authored more than 100 publications in high-impact journals such as Journal of Clinical Oncology, Cancer Epidemiology, Biomarkers & Prevention, Journal of Thoracic Oncology, Cancer, Nature Medicine Clinical Oncology, and Molecular Cancer Therapeutics. She is an active member of many national and international oncology societies, including the International Association for the Study of Lung Cancer (IASLC), and the Mesothelioma Applied Research Foundation (MARF). She was selected to participate in the (ASCO) leadership development program, and assists ASCO and the American Association for Cancer Research (AACR) in lobbying US congressional leaders for improved funding for cancer research.